Syncell is a proteomics technology company enabling in situ protein drug target discovery.
Syncell has raised $15.0M in total funding. The most recent round was Series A. The last funding was announced in December 2024.
Syncell's investors include Taiwania Capital Management Corporation, Darwin Venture Management.
Syncell is headquartered in Watertown, United States.
Syncell is a proteomics technology company enabling in situ protein drug target discovery.
Syncell is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Syncell — Funding & Investors." VCBacked, December 11, 2024, https://www.vcbacked.co/company/syncell. Accessed September 15, 2026.
VCBacked. (2024). Syncell — Funding & Investors. Retrieved September 15, 2026, from https://www.vcbacked.co/company/syncell
{{cite web |title=Syncell — Funding & Investors |url=https://www.vcbacked.co/company/syncell |website=VCBacked |access-date=September 15, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated